CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Terbutaline +2 moredrug
Likely dose
Terbutaline 2.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00974051
NCT00974051N/ACompleted
CompareCT.gov

The Effect of Using Terbutaline or a Reduction in Basal Insulin Infusion as a Therapeutic Agent to Prevent Delayed Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes

University of Colorado, Denver·interventional·Posted Sep 10, 2009·Updated Oct 11, 2013

In Brief

A clinical study evaluating Terbutaline, 20% basal insulin reduction, and 1 other intervention for Type 1 Diabetes. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The investigators hypothesize that the use of an oral dose of Terbutaline or a 20% basal reduction will be able to prevent nocturnal hypoglycemia after an afternoon exercise session. This is a randomized three period cross-over study including treatment with Terbutaline, a 20% basal reduction for six hours, or no treatment (control).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 10, 2009
Enrollment StartMar 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.8 years ago

Interventions

Terbutalinedrug

Oral (2.5mg) one time administration at 9:00pm

20% basal insulin reductionother

Basal insulin rate is reduced by 20% the normal (home dose) for six hours.

Controlother

No treatment is given for the study. This arm is for comparison with the two intervention arms.